Dr. Rose has dedicated his career to immunology translational medicine and advancing new treatment options for autoimmune patients. In various leadership roles, he has brought forward more than a ...

Gene editing firm CRISPR Therapeutics has announced a collaboration with US biotech Nkarta to develop natural killer (NK) cell therapies for cancer. This latest agreement follows a major deal with ...

Nkarta, Inc. (NKTX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

May 14, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq ... trial will receive supplemental cytokines or antibody-based therapeutics. This approach is designed to evaluate the single-agent activity ...

SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies ...

May 14, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NKTX), a clinical-stage ... will receive supplemental cytokines or antibody-based therapeutics. This approach is designed to evaluate the single ...

May 14, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical ... no patients in either trial will receive supplemental cytokines or antibody-based therapeutics.

Q1 net loss of $0.43 per share beat the consensus estimate of a $0.44 loss. Nkarta holds $351.9 million in cash and expects it to last through 2029. Get access to the leaderboards pointing to ...

Nkarta Inc. (NASDAQ:NKTX) on Wednesday reported a first-quarter loss of 43 cents per share, beating the consensus loss of 44 cents. As of March 31, 2025, Nkarta had $351.9 million in cash, cash ...